Mural to Present and Host 1x1 Investor Meetings at the 14th Annual East Coast IDEAS Investor Conference
June 05, 2024 16:15 ET
|
Mural Oncology, Inc.
WALTHAM, Mass. and DUBLIN, June 05, 2024 (GLOBE NEWSWIRE) -- Mural Oncology plc (Nasdaq: MURA), a clinical-stage immuno-oncology company developing novel, investigational engineered cytokine...
Osteal Therapeutics Closes $50M Series D Financing to Support Approval and Commercial Launch of Lead Candidate
June 05, 2024 09:00 ET
|
Osteal Therapeutics
Osteal Therapeutics secured $50M in Series D financing led by Zimmer Biomet. The funds will advance VT-X7, a treatment for periprosthetic joint infection.
Cytokinetics Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
June 04, 2024 16:00 ET
|
Cytokinetics, Incorporated
SOUTH SAN FRANCISCO, Calif., June 04, 2024 (GLOBE NEWSWIRE) -- Cytokinetics, Incorporated (Nasdaq: CYTK) today announced that on May 31, 2024 it granted stock options to purchase an aggregate of...
Lumos Pharma Announces New Analyses of Phase 2 OraGrowtH212 Trial Presented at ENDO 2024
June 04, 2024 09:00 ET
|
Lumos Pharma, Inc.
AUSTIN, Texas, June 04, 2024 (GLOBE NEWSWIRE) -- Lumos Pharma, Inc. (NASDAQ:LUMO), a clinical-stage biopharmaceutical company focused on therapeutics for rare diseases, announced today details of...
Generation Food Rural Partners Launches BioCloak to Enable Truly Sustainable Active Ingredient Encapsulation, Appoints CEO
June 04, 2024 09:00 ET
|
Big Idea Ventures, LLC
Generation Food Rural Partners Launches BioCloak to Enable Truly Sustainable Active Ingredient Encapsulation, Appoints CEO
ADC Therapeutics Makes Grants to New Employees Under Inducement Plan
June 03, 2024 16:05 ET
|
ADC Therapeutics SA
LAUSANNE, Switzerland, June 03, 2024 (GLOBE NEWSWIRE) -- ADC Therapeutics SA (NYSE: ADCT) today announced that the Company has made grants of options to purchase an aggregate of 109,800 of the...
AUROBAC THERAPEUTICS Presents its R&D Strategy & Pipeline and Announces New Development Program in Partnership with Boehringer Ingelheim
June 03, 2024 08:14 ET
|
AUROBAC THERAPEUTICS
AUROBAC THERAPEUTICS to advance ATX101 in septic shock, and multiple preclinical and discovery programs targeting Gram-negative pathogens. Lyon (France), June 3, 2024 AUROBAC THERAPEUTICS, a...
Precede Biosciences Presents New Data at ASCO 2024 Demonstrating Accurate HER2 Status Detection Across Multiple Cancers and the Ability to Quantify ER Pathway Activation in Breast Cancer from a Simple Blood Test
June 02, 2024 10:00 ET
|
Precede Biosciences, Inc.
HER2 status was accurately assessed in 172 patients with advanced breast, gastroesophageal, and ovarian cancersER status was accurately assessed and the level of ER pathway activation quantified in 87...
Data and Safety Monitoring Board Approves Simultaneous Enrollment in Cohort 3 and Phase 2 Initiation in OCU410 ArMaDa study for Geographic Atrophy
May 31, 2024 08:36 ET
|
Ocugen
Established Medium Dose as Safe and Tolerable Dose in Current OCU410 Clinical TrialDSMB Recommends Continuing with High-Dose Cohort Dosing with Concurrent Phase 2 Dosing MALVERN, Pa., May 31, 2024 ...
ONCOTELIC TO PARTICIPATE AT THE BIO INTERNATIONAL 2024 MEETING
May 30, 2024 09:55 ET
|
Oncotelic Therapeutics, Inc.
AGOURA HILLS, Calif., May 30, 2024 (GLOBE NEWSWIRE) -- Oncotelic Therapeutics, Inc (OTCQB:OTLC) announced today its CEO- Dr. Vuong Trieu will be participating at the BIO International 2024 meeting...